Sunday, October 14, 2018 11:28:29 PM
Acquainting yourself with The Legendary BAKER BROS AMRN's largest shareholder 13.5% and 40 mln shrs background
IIRC both brothers (one is a Stanford PHD in Immunology and the other was a deal make/Lawyer from First Boston decided to run money.) So back in the early 2000 period BEFORE they opened the fund up to Pension Funds, was bequeathed ~$100 mln to manage strictly in BioTechs from none other than the multi-billionaire NYC's super businessman and major NYC philanthropist Larry Tisch:
https://en.wikipedia.org/wiki/Laurence_Tisch
NOW for the Baker Brothers
https://seekingalpha.com/article/1906261-following-smart-money-baker-brothers-llc-investments-in-2013-and-beyond
to this in 2016
:https://seekingalpha.com/article/4165526-institutional-top-ideas-series-baker-brothers
The Baker Brothers are ACTIVE mgrs(usually have seat(S) on some of their holdings advising mgt and FULLY BioTechs the highest risk of all: NO Big Pharmas in their portfolio AND CONCENTRATED positions despite managing ~$15 BLN now from $100 mln in early 2000 period.The Baker Brothers Fund is the largest fully dedicated Biotech Fund PERIOD.
The above is a FAST rundown.
DIFFERENT STROKES FOR DIFFERENT FOLKS
PS Just happened to see this post and have not looked at postings diligently.
Special Note to North4000 and JesseLivermore: IIRC Sagamo many years back was one of the top ten holdings of The Baker Brothers.
IIRC both brothers (one is a Stanford PHD in Immunology and the other was a deal make/Lawyer from First Boston decided to run money.) So back in the early 2000 period BEFORE they opened the fund up to Pension Funds, was bequeathed ~$100 mln to manage strictly in BioTechs from none other than the multi-billionaire NYC's super businessman and major NYC philanthropist Larry Tisch:
Through acquisitions, Tisch built Loews' into a highly profitable conglomerate (with 14 hotels, 67 movie theaters, CNA Financial, Bulova, and Lorillard) with revenues increasing from $100 million in 1970 to more than $3 billion in 1980.[3]
In 2002, the year before Larry Tisch's death, the corporation had revenues of more than $17 billion and assets of more than $70 billion
NOW for the Baker Brothers
https://seekingalpha.com/article/1906261-following-smart-money-baker-brothers-llc-investments-in-2013-and-beyond
to this in 2016
:https://seekingalpha.com/article/4165526-institutional-top-ideas-series-baker-brothers
The Baker Brothers are ACTIVE mgrs(usually have seat(S) on some of their holdings advising mgt and FULLY BioTechs the highest risk of all: NO Big Pharmas in their portfolio AND CONCENTRATED positions despite managing ~$15 BLN now from $100 mln in early 2000 period.The Baker Brothers Fund is the largest fully dedicated Biotech Fund PERIOD.
The above is a FAST rundown.
DIFFERENT STROKES FOR DIFFERENT FOLKS
PS Just happened to see this post and have not looked at postings diligently.
Special Note to North4000 and JesseLivermore: IIRC Sagamo many years back was one of the top ten holdings of The Baker Brothers.
DIFFERENT STROKES FOR DIFFERENT FOLKS
Recent AMRN News
- Amarin Highlights New REDUCE-IT Analysis Showing Risk-Weighted ApoB May Improve Cardiovascular Risk Detection (AMRN) • IH Market News • 05/27/2026 03:24:38 PM
- New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia • GlobeNewswire Inc. • 05/27/2026 12:00:00 PM
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
